Are GLP-1 Weight Loss Drugs Worth the Cost Compared to Surgery? A Cost-Effectiveness Review | Research

The takeaway

At current prices, GLP-1 receptor agonists rarely meet accepted cost-effectiveness thresholds for obesity treatment, while bariatric surgery is the most cost-effective option for moderate-to-severe obesity.

25-30% vs 15-20% Weight Loss
Bariatric surgery achieves more weight loss than GLP-1 drugs at lower long-term cost, making it the most cost-effective treatment for moderate-to-severe obesity

What the researchers found

The review's comparative findings across obesity treatment modalities:

- **GLP-1 receptor agonists**: ~15-20% weight reduction, but high ongoing costs place ICERs above conventional willingness-to-pay benchmarks, meaning they rarely meet standard cost-effectiveness thresholds at current pricing.

- **Endoscopic sleeve gastroplasty (ESG)**: ~15% weight loss with favorable cost-effectiveness, particularly in class I obesity (BMI 30-35).

- **Metabolic/bariatric surgery (MBS)**: 25-30% weight loss with improvements in survival and quality of life. Consistently rated highly cost-effective and sometimes cost-saving, especially for class II (BMI 35-40) and class III (BMI 40+) obesity.

ESG is generally more economically favorable than GLP-1 RAs in class I obesity, while MBS dominates for more severe obesity. Head-to-head ESG vs. MBS comparisons remain limited.

Why it matters

GLP-1 drugs are generating billions in revenue as obesity treatments, but this review raises a critical question: are they good value? With annual costs often exceeding $10,000-15,000 per patient indefinitely, they fail standard cost-effectiveness tests. This has major implications for insurance coverage decisions, healthcare budgets, and individual patients weighing their options — particularly as cheaper alternatives like surgery offer more weight loss at lower long-term cost.

How the study worked

Narrative review synthesizing evidence from published clinical studies and health economic analyses. The authors compared incremental cost-effectiveness ratios (ICERs) and cost per quality-adjusted life year (QALY) across obesity severity classes. Special attention was given to implications for Korea's healthcare system.

What this study cannot tell us

This is a narrative review, not a systematic analysis or meta-analysis. Cost-effectiveness data varies significantly by country, healthcare system, and pricing structure — the Korean context focus limits generalizability. GLP-1 drug prices are evolving rapidly with new entrants and competition. The review does not account for patient preferences, quality of life during treatment, or the psychological impact of surgery versus medication. Long-term data beyond 5 years is limited for newer GLP-1 agents.

How to read the evidence

This is a narrative review of published economic analyses and clinical trial data. While it synthesizes strong individual studies, the review itself does not perform original economic modeling or systematic evidence assessment. Cost-effectiveness conclusions depend heavily on pricing assumptions that vary by market.

When this study was published

Published in 2025, this review reflects the most current economic data on GLP-1 obesity treatments including semaglutide and tirzepatide, though pricing is evolving rapidly in this market.

The bigger picture

The explosive growth of GLP-1 peptide drugs is straining healthcare budgets worldwide. This review contextualizes them within the broader obesity treatment landscape, showing that pharmacological convenience comes at a significant cost premium. As GLP-1 drug prices face increasing scrutiny and generic competition approaches, the cost-effectiveness equation may shift. Meanwhile, this analysis supports expanding access to surgical options that deliver superior long-term outcomes at lower total cost.

Questions still open

At what price point would GLP-1 receptor agonists become cost-effective compared to surgical interventions?
How does the cost-effectiveness picture change for patients who cycle on and off GLP-1 drugs versus sustained use?
Could combination approaches (short-term GLP-1 RA use followed by ESG or MBS) optimize both outcomes and cost-effectiveness?

Common questions

Are Wegovy and similar GLP-1 drugs worth the cost for weight loss?

According to this review, GLP-1 drugs achieve significant weight loss (15-20%) but at current prices they rarely meet standard cost-effectiveness thresholds used by health economists. The ongoing cost of indefinite treatment is a key factor — unlike surgery, which is a one-time expense, GLP-1 drugs must be taken continuously to maintain weight loss. Bariatric surgery offers more weight loss (25-30%) at lower total long-term cost.

Which obesity treatment offers the best value for money?

For moderate-to-severe obesity (BMI 35+), bariatric surgery is consistently the most cost-effective option and can even save money overall through reduced healthcare costs from obesity-related diseases. For milder obesity (BMI 30-35), endoscopic sleeve gastroplasty shows favorable economics. GLP-1 peptide drugs, while effective, are the least cost-effective option at current pricing due to their high ongoing costs.

Read the original research

Cost-Effectiveness of Obesity Treatments: Glucagon-Like Peptide-1 Receptor Agonists, Endoscopic Sleeve Gastroplasty, and Metabolic/Bariatric Surgery.

Journal of metabolic and bariatric surgery, 14(2), 97-105

View on PubMed ↗Publisher’s paper ↗

Citation

Huh, Yeon-Ju. (2025). Cost-Effectiveness of Obesity Treatments: Glucagon-Like Peptide-1 Receptor Agonists, Endoscopic Sleeve Gastroplasty, and Metabolic/Bariatric Surgery.. Journal of metabolic and bariatric surgery, 14(2), 97-105. https://doi.org/10.17476/jmbs.2025.14.2.97